TrialSafety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Trial details
- Registry ID
- NCT02968004
- Phase
- Phase 3
Drug research
MOD-4023
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Somatrogon
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02968004 | OPK | Phase 3 | Completed | 2019-08Actual |
| Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02500316 | OPK | Phase 2 | Completed | 2023-11Actual |
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Trial details
- Registry ID
- NCT02500316
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |